Steven Mickelsen
CEO

The startup develops pulsed electric technology that utilizes microbursts of energy delivered via catheter to disrupt cardiac cells. This approach enhances the efficacy of cardiac ablation treatments while minimizing unintended consequences associated with traditional methods.
Raised to date
$40.9MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Current cardiac ablation treatments often suffer from limited efficacy and can cause unintended damage to surrounding tissues due to the use of heat or cold. This can lead to incomplete lesion formation and potential complications for patients undergoing these procedures.
Field Medical is developing pulsed field ablation (PFA) technology to improve cardiac ablation outcomes. Their FieldForce™ Ablation System delivers microbursts of energy via a catheter to selectively disrupt cardiac cells without relying on thermal mechanisms. This approach aims to enhance the precision and effectiveness of ablation procedures while minimizing damage to adjacent structures. The company's technology is designed to address the limitations of existing ablation methods, offering a potentially safer and more efficient treatment option for patients with cardiac arrhythmias. The FieldForce™ system has received FDA Breakthrough Device designation for the treatment of Ventricular Tachycardia.
The primary target audience includes electrophysiologists, cardiologists, and hospitals specializing in cardiac ablation procedures.